Устойчивость к противомикробным препаратам и роль пробиотиков в ее преодолении

Abstract

The concept of risk management and the ideology of microbiocenosis-oriented therapy can be one of the simple and understandable approaches to the formation of modern ideas about the possibilities of integrated use of antibiotics and probiotics as components of effective antimicrobial therapy. In addition to traditional bacterial probiotics, Saccharomyces boulardii CNCM I-745, which has a number of advantages for the realization of such a therapy strategy, are widely used in real practice. The affiliation of S. boulardii CNCM I-745 to fungi makes it possible to use them in any regimen of complex therapy, including antibacterial drugs. This approach improves treatment compliance, ultimate efficacy of therapy and reduces the likelihood of adverse drug reactions. S. boulardii CNCM I-745 are able to reduce the number of genes encoding antimicrobial resistance (ARG) by modulating the intestinal microbiota and controlling the number of bacteria actively forming the pool of ARG, activation of the immune system, which allows to implement antimicrobial effects against pathogens at early stages of the infectious process, production of saturated fatty acids that have antimicrobial properties and have synergistic effects with other antimicrobial drugs. Key words: antibiotic, antimicrobial resistance, resistome, Saccharomyces boulardii, mycobiome